Literature DB >> 31548185

Population Pharmacokinetics of Doxycycline in Children.

Elizabeth J Thompson1, Huali Wu2, Chiara Melloni2, Stephen Balevic1,2, Janice E Sullivan3, Matthew Laughon4, Kira M Clark5, Rohit Kalra6, Susan Mendley7, Elizabeth H Payne8, Jinson Erinjeri8, Casey E Gelber8, Barrie Harper2, Michael Cohen-Wolkowiez1,2, Christoph P Hornik9,2.   

Abstract

Doxycycline is a tetracycline-class antimicrobial labeled by the United States (U.S.) Food and Drug Administration for children >8 years of age for many common childhood infections. Doxycycline is not labeled for children ≤8 years of age, due to the association between tetracycline class antibiotics and tooth staining, although doxycycline may be used off-label in severe conditions. Accordingly, there is a paucity of pharmacokinetic (PK) data to guide dosing in children 8 years and younger. We leveraged opportunistically-collected plasma samples after intravenous (IV) and oral doxycycline doses received per standard of care to characterize the PK of doxycycline in children of different ages, and evaluated the effect of obesity and fasting status on PK parameters.We developed a population PK model of doxycycline using data collected from 47 patients 0-18 years of age, including 14 participants ≤8 years. We developed a 1 compartment PK model and found doxycycline clearance to be 3.32 L/h/70 kg and volume to be 96.8 L/70kg for all patients; comparable to values reported in adults. We estimated a bioavailability of 89.6%, also consistent with adult data. Allometrically scaled clearance and volume of distribution did not differ between children 2 to ≤8 years of age and children >8 to ≤18 years of age, suggesting that younger children may be given the same per kg dosing. Obese and fasting status were not selected for inclusion in the final model. Additional doxycycline PK samples collected in future studies may be used to improve model performance and maximize its clinical value.
Copyright © 2019 American Society for Microbiology.

Entities:  

Year:  2019        PMID: 31548185      PMCID: PMC6879254          DOI: 10.1128/AAC.01508-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.938


  37 in total

Review 1.  Mechanism-based concepts of size and maturity in pharmacokinetics.

Authors:  B J Anderson; N H G Holford
Journal:  Annu Rev Pharmacol Toxicol       Date:  2008       Impact factor: 13.820

2.  Population pharmacokinetics of valsartan in pediatrics.

Authors:  Bahru Habtemariam; William Sallas; Gangadhar Sunkara; Steven Kern; Venkateswar Jarugula; Goonaseelan Pillai
Journal:  Drug Metab Pharmacokinet       Date:  2009       Impact factor: 3.614

3.  Doxycycline and staining of permanent teeth.

Authors:  M E Lochary; P B Lockhart; W T Williams
Journal:  Pediatr Infect Dis J       Date:  1998-05       Impact factor: 2.129

Review 4.  The role of population PK-PD modelling in paediatric clinical research.

Authors:  Roosmarijn F W De Cock; Chiara Piana; Elke H J Krekels; Meindert Danhof; Karel Allegaert; Catherijne A J Knibbe
Journal:  Eur J Clin Pharmacol       Date:  2010-03-26       Impact factor: 2.953

5.  Should clearance be normalised to body surface or to lean body mass?

Authors:  T H Hallynck; H H Soep; J A Thomis; J Boelaert; R Daneels; L Dettli
Journal:  Br J Clin Pharmacol       Date:  1981-05       Impact factor: 4.335

6.  Standardized visual predictive check versus visual predictive check for model evaluation.

Authors:  Diane D Wang; Shuzhong Zhang
Journal:  J Clin Pharmacol       Date:  2011-01-21       Impact factor: 3.126

Review 7.  Doxycycline.

Authors:  B A Cunha; C M Sibley; A M Ristuccia
Journal:  Ther Drug Monit       Date:  1982       Impact factor: 3.681

8.  Dexmedetomidine pharmacokinetics in the obese.

Authors:  Luis I Cortínez; Brian J Anderson; Nick H G Holford; Valentina Puga; Natalia de la Fuente; Hernán Auad; Sandra Solari; Fidel A Allende; Mauricio Ibacache
Journal:  Eur J Clin Pharmacol       Date:  2015-09-26       Impact factor: 2.953

Review 9.  Biowaiver monographs for immediate release solid oral dosage forms: Doxycycline hyclate.

Authors:  E Jantratid; S Strauch; C Becker; J B Dressman; G L Amidon; H E Junginger; S Kopp; K K Midha; V P Shah; S Stavchansky; D M Barends
Journal:  J Pharm Sci       Date:  2010-04       Impact factor: 3.534

Review 10.  Revisiting doxycycline in pregnancy and early childhood--time to rebuild its reputation?

Authors:  Ruby Cross; Clare Ling; Nicholas P J Day; Rose McGready; Daniel H Paris
Journal:  Expert Opin Drug Saf       Date:  2016-01-25       Impact factor: 4.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.